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How the cell converts graded signals into threshold-
activated responses is a question of great biological relevance.
Here, we uncover a nonlinear modality of epidermal
growth factor receptor (EGFR)-activated signal transduc-
tion, by demonstrating that the ubiquitination of the EGFR
at the PM is threshold controlled. The ubiquitination
threshold is mechanistically determined by the coopera-
tive recruitment of the E3 ligase Cbl, in complex with
Grb2, to the EGFR. This, in turn, is dependent on the
simultaneous presence of two phosphotyrosines, pY1045
and either one of pY1068 or pY1086, on the same EGFR
moiety. The dose–response curve of EGFR ubiquitination
correlate precisely with the non-clathrin endocytosis
(NCE) mode of EGFR internalization. Finally, EGFR-NCE
mechanistically depends on EGFR ubiquitination, as the
two events can be simultaneously re-engineered on a
phosphorylation/ubiquitination-incompetent EGFR back-
bone. Since NCE controls the degradation of the EGFR, our
findings have implications for how the cell responds to
increasing levels of EGFR signalling, by varying the
balance of receptor signalling and degradation/attenuation.
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Introduction
The conversion of graded stimuli into switch-like, threshold-
controlled, biological outputs presents the cell with different
challenges according to whether the signal has to be resolved
in space or in time. The former case is exemplified by
the specification of boundaries during patterning in
development. In this instance, the process is frequently
instructed by morphogens that diffuse from a localized
source to create a gradient in an area of unpatterned cells.
Within this area, the graded morphogenetic signal is trans-
duced into sharp response borders: a process that requires the
activation of threshold-controlled mechanisms, and that has
been analysed in various developmental contexts (see for
instance, Ashe and Briscoe, 2006; Lander, 2007; Barkai
and Shilo, 2009).
A different biological setting is represented by those
occurrences in which the gradient is not extended in
space, but in which cells must enact strategies to respond
to varying concentrations of a stimulus, such as a growth
factor. In this context, one obvious possibility is that cellular
responses are directly proportional to the stimulus, that is,
graded input elicits graded output. Another, not mutually
exclusive, possibility is that some signalling events are
threshold controlled. In the case of the epidermal growth
factor (EGF), we have recently uncovered a phenotype that
might be underpinned by such a mechanism. The EGF
receptor (EGFR) is internalized through both clathrin-
mediated endocytosis (CME) and non-clathrin endocytosis
(NCE). However, while CME is active at all ligand
concentrations, NCE is observed only when high EGF con-
centrations are applied to cells (Lund et al, 1990; Yamazaki
et al, 2002; Sigismund et al, 2005; Orth et al, 2006;
Sigismund et al, 2008), suggesting that it might be
threshold controlled.
The functional meaning and relevance of EGFR-NCE is
still somehow obscure. For instance, its presence depends on
the cellular context ((Sigismund et al, 2005; Kazazic et al,
2006; Orth et al, 2006; Madshus and Stang, 2009; Rappoport
and Simon, 2009), see also Results in this paper). In the
cellular populations in which EGFR-NCE is active, however,
it might impinge heavily on the regulation of EGFR
signalling, since we have shown that while CME is
primarily coupled with EGFR recycling to the cell surface
(and therefore with sustainment of signalling), NCE is
largely devoted to commit the receptor to lysosomal
degradation (Sigismund et al, 2008). Thus, the sharp
activation of NCE above a certain ligand threshold (while
CME nevertheless persists) might regulate the net signalling
output, in response to increasing EGF concentrations, in a
nonlinear fashion.
Intriguingly, a post-translational modification of the EGFR,
that is, EGFR ubiquitination, might also be threshold con-
trolled, as we have shown that pronounced EGFR ubiquitina-
tion occurs only at high EGF concentrations (Sigismund et al,
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2005, 2008). EGFR ubiquitination is executed by the E3 ligase
Cbl (Levkowitz et al, 1998, 1999). Cbl is recruited to the
activated EGFR by two distinct mechanisms: it can interact
directly with the receptor at pY1045 (Levkowitz et al, 1999),
or indirectly, through Grb2, at pY1068 or pY1086 (Waterman
et al, 2002; Jiang et al, 2003). A possible mechanistic link
between EGFR ubiquitination and EGFR-NCE was provided
by the observation that an ubiquitination-impaired mutant of
the EGFR (Y1045F) (Levkowitz et al, 1999) is internalized
exclusively through CME, regardless of the concentration of
EGF (Sigismund et al, 2005, 2008). Thus, one could
hypothesize a threshold-controlled scenario in which a
linear EGF signal is converted, above a certain dose, in a
ubiquitination signal, which in turn switches on the NCE
mode of EGFR internalization. The present studies were
undertaken to test this possibility and to experimentally
challenge various mechanistic models through which this
might occur.
Results
A threshold effect for EGFR ubiquitination
Upon EGF treatment, the ubiquitination of the EGFR—
measured by immunoblot (IB)—increased sharply over a
narrow range of EGF concentrations, being minimal at 1ng/ml
and nearly maximal at 10 ng/ml, both in epithelial cells
(HeLa) and in fibroblasts (NR6-EGFR cells) (Figure 1A).
Conversely, the EGFR phosphotyrosine (pY) content, used
as a surrogate for receptor activation, displayed a typical
hyperbolic dose–response curve, which translated in a semi-
linear behaviour when a log scale was used for EGF doses
(Figures 1A and B and Supplementary Figures 1A-C; see also
Supplementary Figures 1D–F for a series of specificity con-
trols). More precisely, the dose–response curves for EGFR
phosphorylation and ubiquitination displayed different
degrees of sigmoidicity, best approximated by Hill functions
with Hill coefficients (nH) of 1 and 3, respectively.
Figure 1 Analysis of EGFR ubiquitination. (A) HeLa or NR6 cells were stimulated with the indicated concentrations of EGF for 2min (in this
and all subsequent figures). IP and IB were performed as indicated (Ub, ubiquitin P4D1 antibody). (B) HeLa cells were stimulated with EGF,
followed by IB with the indicated antibodies. (C, D) Lysates of HeLa cells stimulated with EGF, as indicated, were subjected to ELISA, forward
approach (Supplementary Figure 2A), using the indicated detecting Ab (Ub, FK2 antibody). Results are shown as % of max (see Materials and
methods). (E) Lysates of HeLa cells stimulated with EGF, as indicated, were subjected to ELISA, reverse approach (Supplementary Figure 2B),
using the indicated detecting Ab (Ub, FK2 antibody). (F) Comparison of the EGFR ubiquitination and phosphorylation curves of HeLa cells
obtained by forward and reverse ELISA. In all panels (and in all subsequent figures), error bars indicate s.d. calculated on at least three
independent experiments. P-values were calculated using two-way ANOVA analysis. When comparing curves that showed significant
differences (in all figures), we show the relative P-values; when comparing curves that did not show significant differences (in all figures),
we display R, the Pearson correlation coefficient. Source data for this figure is available on the online supplementary information page.
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To obtain independent quantitative measurements, we
exploited an ELISA-based approach (Supplementary Figures 2A
and B). In this assay, performed both as a ‘forward’ or
‘reverse’ ELISA, the dose–response curve of EGFR ubiquitina-
tion was clearly different from those of EGFR-pY or of
individual phosphosites and displayed an evident threshold
effect (Figures 1C–F and Supplementary Figure 2C).
We also performed quantitative mass spectrometry (MS)
analysis (that is, SILAC, stable isotope-labelled amino acid in
cell culture) of EGFR ubiquitination and tyrosine phosphor-
ylation (Figures 2A and B and Supplementary Figure 3A). The
amount of ubiquitin peptides in EGFR-enriched preparation
of cells stimulated with different EGF doses was compared to
the amount obtained upon stimulation with EGF at the
maximal dose (100 ng/ml). Also by this method, a clear
threshold effect for total EGFR ubiquitination was visible
(Figures 2C and D and Supplementary Figures 3B and C),
with quantitative estimates obtained by MS and ELISA
almost coincident (Figure 2D, bottom). Importantly, we
could unequivocally identify a ubiquitinated EGFR peptide,
corresponding to K692-Ub and previously identified as one of
the major EGFR-Ub sites (Huang et al, 2006), which also
showed a threshold behaviour (Figure 2E, top), while
several EGFR-pY sites displayed more gradual increments
(Supplementary Figures 3D–F). The mean ratio of
different phosphosites is reported in Figure 2E bottom.
Figure 2 SILAC-MS for quantitative analysis of ubiquitinated and phosphorylated EGFR. (A) Schematic representation of the SILAC-MS
approach. HeLa cells were grown in SILAC-encoded ‘light’ or ‘heavy’ media (Supplementary Experimental Procedures). ‘Light’ (L) cells were
stimulated with 100 ng/ml of EGF; ‘heavy’ (H) cells were treated independently with increasing concentrations of EGF, as indicated. Cells were
then harvested and mixed (H/L) in 1:1 ratio for each pair. (B) Lysates from the seven H/L mixtures were subjected to anti-EGFR IP and SDS–
PAGE. Lanes were cut (shown by red lines) starting from the position of the EGFR (asterisk), to cover potential differentially ubiquitinated
forms. (C) Left, LTQ-FTICR mass spectra of Ub (UBC, peptide 11–27, left) and EGFR (peptide 81–98, right) from each H/L mixture (a more
detailed representation is in Supplementary Figures 3B and C). (D) Threshold ubiquitination of EGFR, detected by MS. Top, high-accuracy
quantification of total EGFR (87) and Ub (13) peptides; see Supplementary Table 1 for raw data. Bottom, comparison of EGFR-Ub data obtained
with forward ELISA (Figure 1C) and SILAC-MS (from top panel). R, Pearson correlation coefficient. (E) Top, SILAC ratios of the EGFR
ubiquitination site (K692-Ub) shown in Supplementary Figure 3G. Bottom, mean SILAC ratios of EGFR phosphorylation were calculated on the
basis of the three pY sites shown in Supplementary Figures 3D–F. Note that, while mean pY increases linearly upon EGF stimulation (R2¼ 0.97,
square of correlation coefficient; see also Supplementary Figures 3D–F for the linear behaviour of single pY sites), the abundance of the EGFR-
Ub peptide increases with a threshold behaviour, similarly to total Ub (panel D). SILAC ratios are calculated using MaxQuant (see
Supplementary Figures 3H–K for more detailed pictures).
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Additional technical information on the MS experiments
is reported in Supplementary Figures 3G–K and in
Supplementary Table 1.
We concluded that EGFR ubiquitination is threshold
controlled.
The threshold effect for EGFR ubiquitination occurs
at the PM
One of the goals of this study is to establish a mechanistic
connection between EGFR ubiquitination and EGFR-NCE
(see below). It was critical, therefore, to establish that
the threshold effect was already operative at the PM,
where internalization occurs. For this reason, we performed
all experiments after 2min of EGF treatment, when EGFR
internalization is minimal. However, since it is known
that EGFR ubiquitination begins at the PM and continues in
endosomes (Umebayashi et al, 2008), it was also necessary
to determine exactly where the observed EGFR ubiquitination
threshold occurred, under our experimental conditions.
To address this question, we inhibited both CME and NCE
internalization of the EGFR, by silencing the expression of
dynamin 2 in HeLa cells (Figures 3A and B), and then
analysed ligand-induced EGFR ubiquitination. The threshold
effect for EGFR ubiquitination, evidenced both by IB
(Figure 3A) and—quantitatively—by ELISA (Figure 3C), per-
sisted in dynamin 2-knockdown (KD) cells, thus proving that
it occurs at the PM. In addition, the magnitude of both EGFR
ubiquitination and tyrosine phosphorylation was comparable
in KD and wild-type (WT) cells (Figure 3A), arguing that—
under our conditions of analysis—the vast majority of these
events takes place at the PM. We note that our results do not
imply that endosomal ubiquitination of EGFR is not threshold
controlled, but simply that the threshold effect occurs already
at the PM.
A threshold effect for Cbl recruitment to the EGFR
EGFR ubiquitination is executed by the E3 ligase Cbl
(Levkowitz et al, 1998, 1999). We investigated how the
activity of Cbl is controlled in the cell to produce the EGFR
ubiquitination threshold.
The Cbl family is composed of three genes, c-Cbl, Cbl-b and
Cbl-c (Schmidt and Dikic, 2005; Lipkowitz and Weissman,
2011). By quantitative RT–PCR analysis (Q-PCR), we found
that our HeLa cells express c-Cbl and, to a lower extent, Cbl-b,
but little if any Cbl-c (Figure 4A). The expression level of
c-Cbl and Cbl-b was confirmed by IB (Figure 4B). The
silencing of c-Cbl caused a sizable reduction in EGFR ubiqui-
tination, while silencing of Cbl-b produced modest effects,
even when it was silenced together with c-Cbl (Figure 4C).
We concluded that, in the cellular system under scrutiny,
c-Cbl is the major E3 ligase responsible for EGFR ubiquitina-
tion at the PM. Thus, we concentrated on c-Cbl (henceforth,
Cbl) in the subsequent experiments.
We analysed the association between Cbl and EGFR in vivo.
We detected a clear threshold effect in the EGF-induced
co-immunoprecipitation (co-IP) between the two proteins,
an effect that was not evident when the physical association
of EGFR with other known interactors, such as Grb2 or Shc,
was analysed (Figure 4D, see also Supplementary Figure 4 for
additional experiments relevant to the interaction between
Grb2 and the EGFR). Thus, the association of Cbl with the
EGFR exhibits a unique dose–response behaviour that
correlates with a similar behaviour of the Cbl-mediated
ubiquitination of the EGFR.
Figure 3 The threshold effect for EGFR ubiquitination occurs at the
PM. (A) Top, HeLa cells were subjected to dynamin 2-KD and
treated for 2min with EGF at the indicated concentrations. IP and
IB were as shown. (B) EGFR internalization kinetics in dynamin
2-KD cells was measured using 125I-EGF at low (1 ng/ml) or high
(30ng/ml) EGF concentrations. Results are expressed as the inter-
nalization rate constant (Ke, left panel) or as % of Ke in control cells
(right panel), and are the mean of triplicate points (s.e.m.o8%).
Dynamin 2-KD (Dyn 2-KD) severely impaired EGFR internalization
both at low and high EGF concentrations, reducing rates to back-
ground levels. Similar background levels have previously been
observed by us in clathrin-KDþfilipin-treated HeLa cells, in
which both CME and NCE are inhibited (Sigismund et al, 2005,
2008). These results confirm that both CME and NCE of the EGFR
are dynamin 2 dependent. Comparable results were obtained with
two different silencing oligos for dynamin 2 (data not shown).
(C) Lysates of HeLa cells, control and dynamin 2-KD, stimulated
with EGF for 2min at the indicated concentrations were subjected to
ELISA, forward approach (Supplementary Figure 2A), using anti-Ub
(FK2) and anti-pY as detecting antibodies. Results are shown as a
percentage of the maximal tyrosine phosphorylation or ubiquitina-
tion (% of max, see Materials and methods). Graph error bars
indicate s.d. calculated on at least three independent experiments.
All P-values were calculated using two-way ANOVA analysis. As
shown the Ub curves were not significantly different between
control and KD; the same was true for the pY curves. Conversely,
the Ub curves were significantly different from the pY curves.
Source data for this figure is available on the online supplementary
information page.
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Experimental challenge of models of threshold control
of EGFR ubiquitination
There are several mechanisms that, in principle, could
explain the EGFR ubiquitination threshold. One obvious possi-
bility is that the phosphorylation of individual Cbl-binding
sites on EGFR (pY1045 or one between Y1068 and Y1086)
increases in a sigmoidal fashion with the doses of EGF
(Figure 5A, threshold phosphorylation model). We have,
however, tested and excluded this possibility (Figure 1B).
Indeed, individual EGFR phosphosites do not display thresh-
old phosphorylation, as shown both for the direct (pY1045,
Figure 1B) and for the indirect Cbl-binding phosphosites
(pY1068 or pY1086, Figures 1B and D).
A second group of models is based on either positive or
negative regulation of Cbl. In the first case (threshold Cbl
activation model, Figure 5A), the enzymatic activity of Cbl
could be activated in a nonlinear fashion. It is known that the
activation of Cbl depends on its phosphorylation by EGFR
(Levkowitz et al, 1999; Kassenbrock and Anderson, 2004),
which induces—and possibly stabilizes—an open Cbl con-
formation, required for the interaction with the E2 enzyme
(Dou et al, 2012). However, the EGF-induced Cbl
phosphorylation displays a gradual increment over a range
of EGF concentrations (Figure 5B), arguing against this
hypothesis (see also Supplementary Figure 5 for additional
experiments on Cbl phosphorylation).
Inhibition of Cbl function has been extensively investigated
in the literature (Schmidt and Dikic, 2005; Ryan et al, 2006).
Various permutations of models centred on Cbl-negative
regulation can be envisaged. One example is represented in
the ‘competition model’ (Figure 5A), where there might be
competition between high-affinity and low-affinity proteins
for binding to the EGFR. When the number of binding sites
(pY sites) is limited (as it would occur at low EGF doses),
low-affinity binders (as Cbl hypothetically might be) would
be prevented from interacting with the EGFR. If the number
of high-affinity ligands is limiting, they would be titrated as
the number of binding sites increases, in response to EGF
Figure 4 The EGFR–Cbl interaction is threshold controlled. (A) Q-PCR of c-Cbl, Cbl-b and Cbl-c in HeLa cells. Both Ct values (threshold cycles)
and mRNA level of c-Cbl, Cbl-b and Cbl-c (normalized on 18S mRNA and expressed as fraction of c-Cbl mRNA) are reported. (B) HeLa cells
were subjected to c-Cbl and Cbl-b-KD, alone or in combination (Contr, HeLa cells transfected with control oligo). IB was as shown (Tub,
tubulin; loading control). (C) HeLa cells, transfected with the indicated oligos as in B, were stimulated with EGF as shown. Lysates were
subjected to IP and IB as shown. For the Ub blots: l.e., long exposure; s.e., short exposure. Note that two different oligos targeting c-Cbl and Cbl-
b were used, with comparable results. In panel B and C, results obtained with UTR1 (for both c-Cbl and Cbl-b) are shown (see Materials and
methods for details). (D) Top, HeLa cells were treated with EGF as indicated for 2min and then IP and IB as shown. Bottom, quantitative
assessment. Results are expressed as a percentage of the maximal amount (% of max, see Materials and methods) of EGFR that
coimmunoprecipitates (Co-IP) with c-Cbl (from now on Cbl), Grb2 or Shc. Source data for this figure is available on the online supplementary
information page.
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Figure 5 Models describing the generation of EGFR-Ub threshold. (A) Top, schematic representation of EGFR ubiquitination and EGFR
phosphorylation, as a function of ligand concentration. xT represents the half-maximal EGF dose for EGFR ubiquitination (i.e., the
ubiquitination threshold) and it is used to separate in the pictograms underneath (dashed line) the events occurring at low EGF (left) from
those occurring at high EGF (right). In the inset, the various symbols used in the models are shown. Various models potentially accounting for
the EGFR ubiquitination threshold (in all models the ubiquitination of EGFR by Cbl is indicated by a solid arrow line). 1) Threshold
phosphorylation model. The model contemplates that the phosphorylation of individual Cbl-binding sites on EGFR (pY1045 or one between
Y1068 and Y1086) increases in a sigmoidal fashion with the doses of EGF. The model is depicted for pY1045, but it could be equally applied to
the indirect (Grb2-mediated) binding site(s) (pY1068/pY1086). 2) Threshold Cbl activation model. The model contemplates that the enzymatic
function of Cbl is activated in a nonlinear fashion by signalling events (e.g., direct tyrosine phosphorylation of Cbl by the EGFR, indicated by a
dashed arrow line) that occur only under high EGF. 3) Competition model. This model invokes the existence of a high affinity, rate-limiting
(low amount) competitor X. At low EGF (left), such competitor—that in the model would bind only to activated EGFR—prevents Cbl from
interacting with the EGFR or from ubiquitinating the receptor (in this latter case, either directly inhibiting Cbl activity or masking Ub sites on
the EGFR, not shown). At high EGF (right), the competitor becomes limiting and Cbl could therefore bind and ubiquitinate the EGFR.
4) Cooperative model. Cbl/Grb2 complex binds stably to EGFR only when pY1045 and at least one of pY1068 and pY1086 are present in the
same EGFR molecule. In this case, the EGFR phosphorylation pattern determines the ubiquitination threshold. At low EGF (left), EGFR is
poorly phosphorylated and the probability of having the two key sites in the same EGFR molecule is low (possible low-affinity binding of the
Cbl:Grb2 complex to single sites is shown by a dotted line). However, this probability increases at high EGF (right) allowing for the cooperative
recruitment of Cbl/Grb2. This model implies that phosphorylation sites are phosphorylated independently of one another (as shown
experimentally in Figure 7C and Supplementary Figure 7) and therefore the probability of having one site phosphorylated within the same
EGFR molecule increases gradually with the EGF concentration, while the probability of having two sites increases sharply. (B) EGF dose–
response curve of Cbl phosphorylation. Left, HeLa cells were treated with EGF for 2min as indicated. Lysates were prepared in RIPA buffer
(w/ 1% SDS) and then diluted to 0.2% SDS (see Materials and methods). IP and IB was as shown. Right, quantitation of the blots. Source data
for this figure is available on the online supplementary information page.
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escalation, allowing for the low-affinity ligands to interact with
EGFR. A variation of this scenario, which still relies on
negative Cbl regulation, is represented by a ‘threshold-
controlled relief of inhibition’ model (not shown), which
postulates that negative regulation exerted over Cbl by cellular
factors can be relieved by signalling events emanating from
activated EGFR (e.g., phosphorylations) in a nonlinear fashion.
Finally, a cooperative model can be envisioned
(Figure 5A), postulating that Cbl alone cannot account for
the ubiquitination of EGFR, but it requires the formation of a
complex with Grb2. This would imply that only receptors
harbouring simultaneous phosphorylation of Y1045 (i.e., the
Cbl2-binding site) and Y1045 and/or Y1068 (i.e., Grb2-bind-
ing sites) can effectively bind to Cbl and be thereby ubiqui-
tinated. Such a mechanism might account, at least in part, for
the ubiquitination threshold, in that the probability of having
both sites phosphorylated on the same EGFR molecule would
increase nonlinearly as a function of ligand concentration.
An important insight towards the definition of the correct
model derived from Grb2 silencing experiments. Under these
conditions, EGFR ubiquitination was significantly reduced
(Figure 6A) and—more importantly—there was a switch
from threshold to non-threshold behaviour (Figures 6B and C,
note that IP in Grb2-KD cells was performed with three times
more lysate to have comparable EGFR-Ub signal versus WT
cells). These results define an important property of the
system in vivo, that is, the ubiquitination threshold is Grb2
dependent. To define the molecular mechanism involved, we
set up in vitro EGFR:Cbl association assays and EGFR ubiqui-
tination assays. When GST-Cbl was used to pull down EGFR
from cellular lysates, from cells stimulated with increasing
concentrations of EGF, the curve exhibited a linear (non-
threshold) shape (Figure 6D). However, by adding purified
Grb2 (ten-fold molar excess versus Cbl) to the reaction, the
threshold effect was promptly restored, with an overall
behaviour similar to that observed for the in vivo interaction
(Figure 6D). Next, we set up an in vitro Cbl-dependent EGFR
ubiquitination reaction, in which purified phosphorylated
EGFR was used as a substrate. This assay showed a strong
requirement for the presence of Grb2 for efficient catalysis,
while Cbl alone was not very efficient, despite the presence of
efficient phosphorylation of its direct binding site, Y1045
(Figure 6E). Together the in vitro data establish a causal
link between threshold-controlled (Grb2-mediated) Cbl asso-
ciation with EGFR and its catalytic ability towards the EGFR
(Figures 7 and 8). In addition, the sum of the above results is
Figure 6 Grb2 is required to generate the EGFR-Ub threshold in vivo and in vitro. (A) HeLa cells were subjected to Grb2-KD or transfection
with control oligos. Lysates were stimulated with EGF for 2min as indicated and subjected to IP/IB as indicated. (B) Top, HeLa cells, either
control or Grb2-KD, were stimulated with EGF for 2min at the indicated concentrations. Lysates were subjected to IP and IB as shown. Note
that the Grb2-KD displays approximately three-fold reduced total ubiquitination with respect to control cells (panel A); thus, we used three-fold
more lysate (3 , 1mg for Grb2-KD, 300mg for control) to obtain comparable IB signals. Bottom, quantitative assessment. Results are
expressed as a percentage of the maximal amount (% of max, see Materials and methods) of EGFR ubiquitination. (C) Lysates of HeLa cells,
control and Grb2-KD, stimulated with EGF for 2min at the indicated concentrations were subjected to ELISA, reverse approach (see
Supplementary Figure 2B), using anti-Ub (FK2) as capturing antibody. Results are shown as a percentage of the maximal ubiquitination (% of
max, see Materials and methods). (D) Left, lysates of HeLa cells stimulated with EGF for 2min at the indicated concentrations were subjected
to pull-down assay with 10mg of GST-Cbl as bait, in absence (left panels) or in presence of 10 molar excess bacterially purified Grb2 (right
panels). IB was as shown. Right, quantitation of the blots. (E) In vitro ubiquitination assay. GST-EGFR cytoplasmic tail (250ng) was subjected
to in vitro autophosphorylation reaction and then bound to beads followed by incubation with ubiquitin (1 mg), purified E1 (100 ng), UbcH5c as
E2 (500 ng), Cbl as E3 (500ng), in absence or presence of purified Grb2. IB was as indicated. Results are representative of at least three
experiments. Control reactions without EGFR or without E2 are also shown. All P-values were calculated using two-way ANOVA analysis.
Graph error bars indicate s.d. calculated on at least three independent experiments. Source data for this figure is available on the online
supplementary information page.
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more readily compatible with the cooperativity model than
with models based on negative regulation.
pY1045 and pY1068/1086 are synergistically required for
Cbl recruitment and optimal EGFR ubiquitination
We sought for in vivo evidence to support the cooperativity
model. This model postulates that efficient recruitment of Cbl
to active EGFRs depends on the simultaneous presence of
pY1045 and either one of pY1068 or pY1086. In addition, the
concomitant presence of pY1045 and pY1068/1086 on the
same receptor moiety should increase sharply and non-
gradually as a function of ligand. To test this latter possibility,
we immunoprecipitated EGFR from cellular lysates with an
anti-pY1068 Ab, followed by IB with anti-pY1045 (or with
anti-pY1068 as a control). To exclude artifacts due to EGFR
dimerization, lysates were obtained in the presence of 1%
SDS (to destroy protein–protein interactions) followed by
dilution to working concentrations of SDS (0.2%). As
shown in Figure 7A, the Y1068 phosphorylation curve dis-
played a gradual EGF-dependent increase (similarly to what
is already shown for all analysed individual phosphosites, see
Figure 1B), while the simultaneous phosphorylation of Y1045
and Y1068 on the same EGFR moiety displayed a clear
threshold effect.
Next, we turned to molecular genetics and engineered a
series of mutants in which the relevant phosphosites
(pY1045, pY1068 and pY1086) were altered. Initial experi-
ments with mutants in which these interaction surfaces were
abrogated, alone or in combination, yielded results compa-
tible with the cooperativity model (Supplementary Figure 6).
A more stringent approach, however, required re-engineering
of these surfaces in the absence of other phosphosites that
can contract multiple interactions with unpredictable effects.
Thus, we engineered add-back mutants (Figure 7B) by first
creating a pY-null EGFR backbone (the 9Y- mutant) and then
adding back the Tyr relevant for the cooperativity model
(alone or in combination, 1045þ , 1068/1086þ and 1045/
1068/1086þ mutants, Figure 7B). These mutants were ex-
pressed, at comparable levels (Figure 7B), in cells devoid of
endogenous EGFR. The mutants exhibited EGF-stimulated
gradual (non-threshold) tyrosine phosphorylation, as
expected (Figure 7C and Supplementary Figure 7).
Importantly, they also exhibited intrinsic kinase activity
apparently indistinguishable from WT, as judged by their
ability to autophosphorylate the re-engineered tyrosine resi-
dues (1045 and 1068) as efficiently as EGFR-WT (Figure 7C
and Supplementary Figure 7). Incidentally, these results
imply that, at least for Y1045 and Y1068, tyrosine phosphor-
ylation events are independent of each other and of the
phosphorylation of other sites.
We then tested the in vivo association of the add-back
mutants with Cbl and their EGF-induced ubiquitination.
Compared to EGFR-WT, Cbl association to the 1045þ mutant
was reduced by four- to five-fold, while association with the
1068/86þ mutant was reduced to negligible levels
(Figure 7D). Instead, the association of Cbl with the 1045/
1068/1086þ mutant was indistinguishable from EGFR-WT
(Figure 7D). In addition, there was a clear cooperative effect
of the 1045 and of the 1068/86 phosphosites towards associa-
tion with Cbl (Figure 7D). Similarly, the 1045 and the 1068/
1086 phosphosites exerted a clear cooperative effect also on
EGFR ubiquitination (Figure 7E). Importantly, the ubiquitina-
tion levels of the add-back mutants reflected the levels of
their in vivo binding to Cbl (compare Figures 7D and E).
Together, these results again support the cooperativity model
of interaction of the Cbl:Grb2 complex with the EGFR (see
also Supplementary Figure 4 for additional information), and
argue that this modality of interaction is indeed responsible
for the EGFR ubiquitination threshold.
As a final approach, we analysed whether the ‘sigmoidal’
behaviour of Cbl:EGFR association and of EGFR ubiquitina-
tion could be re-engineered on a pY-null EGFR backbone, by
progressively adding back the relevant phosphosites. To this
end, we compared the EGF dose–response curves of
Cbl:EGFR co-IP and of receptor ubiquitination of the 1045þ
and 1045/1068/1086þ mutants versus EGFR-WT. The dose–
response curves of the 1045/1068/1086þ mutant displayed
threshold behaviours similar to that of EGFR-WT (Cbl:EGFR
Co-IP, Figure 8A; receptor ubiquitination, Figures 8B and C).
Conversely, the 1045þ mutant displayed non-threshold
gradual dose–response curves, consistent with the fact that
its interaction with Cbl depends on a single site (Figures 8A–C).
Thus, the sum of all evidence strongly argues that the thresh-
old effect for EGFR ubiquitination is due to a threshold
mechanism in the recruitment of the Cbl:Grb2 complex,
which is in turn is dependent on cooperativity between
pY1045 and pY1068/1086 of the EGFR.
The ubiquitination threshold is mechanistically linked
to the NCE internalization threshold of the EGFR
We have previously shown that the NCE modality of EGFR
internalization is operative only at relatively high concentrations
Figure 7 Phosphorylation, ubiquitination and association with Cbl of EGFR add-back mutants. (A) Top, HeLa cells were stimulated with EGF
for 2min at the indicated concentrations. Lysates were prepared in 1% SDS-containing lysis buffer (see Materials and methods) and subjected
to IP and/or IB as shown. Eight-tenth of the IP were IB with anti-pY1045; one-tenth each of the IP was IB with anti-pY1068 or anti-EGF. Bottom,
quantitation of the blots shown as % of max. Mean and statistical analysis performed on three independent experiments are shown. (B) Top.
Scheme of the add-back mutants used in this study. The intracellular domain (kinase domain and C-terminal tail) of the EGFR is shown, with
the position of the relevant residues. Critical tyrosine residues involved in Cbl/Grb2 binding are indicated in blue, while the other tyrosine
residues in the EGFR tail are depicted in grey. Bottom, NR6 cells stably expressing EGFR-WTor the indicated mutants were analysed by 125I-EGF
saturation binding and the number of surface receptors was measured. Data are expressed as surface EGFRs/cell. (C) Quantitation of tyrosine
phosphorylation of individual phosphosites in the EGFR add-back mutants (in comparison to EGFR-WT), as a function of EGF dose. Results are
expressed as absolute values in arbitrary units (a.u., 100¼max WT at 100ng/ml EGF, see Materials and methods). Raw data are in
Supplementary Figure 7. (D) Left, cells expressing the indicated mutants were stimulated with EGF (100ng/ml, 2min). Lysates were subjected
to IP and IB as indicated. Right, quantitation of the blots. Results were normalized for the amount of immunoprecipitated EGFR and are
expressed as % of the values obtained in EGFR-WTcells. Mean and statistical analysis performed on three independent experiments are shown.
(E) Left, NR6 cells stably expressing EGFR-WT or the indicated mutants cells were stimulated with EGF (100 ng/ml, 2min). Lysates were
subjected to IP and IB as indicated. Right, quantitation of the Ub blot. Results were normalized for the amount of immunoprecipitated EGFR
and are expressed as % of the values obtained in EGFR-WTcells. Mean and statistical analysis performed on three independent experiments are
shown. Source data for this figure is available on the online supplementary information page.
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of EGF ((Sigismund et al, 2005, 2008), see also various
additional characterizations in Supplementary Figure 8),
suggesting that it might be controlled by some threshold
signals emanating from the receptor. Thus, we sought for
evidence that could mechanistically link the EGFR ubiquitination
threshold to EGFR-NCE.
The notion of EGFR-NCE, however, has been challenged by
reports showing that the internalization of EGFR proceeds
through CME at all tested doses (Kazazic et al, 2006;
Rappoport and Simon, 2009). It was important, therefore, to
first resolve this issue before proceeding with further
analyses. We tested for the presence of a NCE pathway of
EGFR internalization in a panel of cell lines and found
that five of nine lines displayed EGFR-NCE (Table I and
Supplementary Figure 9). We concluded that NCE, although
cell context dependent, is a common mode of EGFR inter-
nalization.
Next, we proceeded to investigate how EGFR ubiquitina-
tion and EGFR-NCE are related. As an initial approach, we
tested the impact of Cbl silencing on the various modalities of
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EGFR internalization. In our HeLa cells, pharmacological
and/or molecular genetics approaches allow to identify
three pathways of internalization, CME, NCE and what we
operationally define as ‘background endocytosis’ (BE), which
corresponds essentially to the residual fraction of endocytosis
upon dynamin 2-KD or upon combined clathrin-KD and
Figure 8 Dose–response behaviour of Cbl-binding and receptor ubiquitination of EGFR add-back mutants. (A) Left, NR6 cells stably
expressing the Y1045þ mutant, the Y1045/68/86þ mutant or EGFR-WT, were stimulated with EGF for 2min at the indicated concentrations.
Lysates were subjected to IP and IB as shown. Note that for the 1045þ mutant, we used two-fold more lysate (2 , 2mg for 1045þ , 1mg for
EGFR-WT and Y1045/68/86þ ) and different washing conditions (see Materials and methods). Right, quantitative assessment. (B) Left, NR6
cells stably expressing the Y1045þ mutant, the Y1045/68/86þ mutant or EGFR-WT, were stimulated with EGF for 2min at the indicated
concentrations. Lysates were subjected to IP and IB as shown. Note that the 1045þ mutant displays approximatley five-fold reduced total
ubiquitination with respect to EGFR-WT (Figure 8A); thus, we used five-fold more lysate (5 , 1mg for 1045þ , 200mg for EGFR-WT and
Y1045/68/86þ ) to obtain comparable IB signals. Right, quantitative assessment. (C) The same samples were subjected to ELISA, forward
approach, using anti-Ub (FK2) as detecting antibodies. Results are shown as a percentage of WTubiquitination (arbitrary units, 100¼max WT,
left panel) or percentage of maximal ubiquitination in each dose–response curve (% of max, right panel, see Materials and methods). Graph
error bars indicate s.d. calculated on at least three independent experiments. All P-values were calculated using two-way ANOVA analysis. R,
the Pearson correlation coefficient. Source data for this figure is available on the online supplementary information page.
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filipin treatment (see Supplementary Figures 8A and B and
Supplementary Experimental Procedures—Definition of
EGFR-NCE and experimental determination of CME and
NCE of the EGFR–). It is of note that both CME and NCE
were sensitive to treatment with EGFR kinase inhibitors,
while BE (assessed by dynamin 2-KD) was essentially un-
affected (Supplementary Figure 8C), thus probably represent-
ing a constitutive kinase-independent pathway, as also
supported by experiments with kinase-dead EGFR mutants
(Supplementary Figure 8D).
At low EGF doses (a condition under which NCE is not
active), the Cbl KD resulted in a B30% decrease of the EGF
internalization rate, similar to what already reported by
others (Bertelsen et al, 2011; Huang et al, 2007). Under the
same conditions, double KDs—Cbl-clathrin or Cbl-dynamin
2—did not result in any worsening of the individual clathrin
or dynamin 2 KD phenotypes, respectively (Figure 9A and
Supplementary Figure 10 for KD levels). At high doses of EGF
(where both CME and NCE are active), the Cbl KD caused a
marked (albeit not complete) reduction in the EGF internali-
zation rate (Figure 9A). Importantly, in a clathrin-KD back-
ground, the Cbl KD was able to further reduce the EGF
internalization rate to levels indistinguishable from those of
BE (measured by dynamin 2 KD). In addition, the double Cbl-
dynamin 2 KD did not worsen significantly the effect of the
dynamin 2 KD alone (Figure 9A). Finally, by knocking down
Grb2 expression, we could also show that EGFR-NCE is Grb2
dependent (Supplementary Figure 11). We concluded that—
in the model system under scrutiny—NCE is completely Cbl
dependent, CME displays a moderate dependency on Cbl, and
BE is independent of it.
Having established that Cbl is absolutely required for NCE,
we proceeded to compare the EGF dose–response curves of
EGFR-NCE and EGFR ubiquitination in HeLa cells. As shown
in Figure 9B, the two curves were almost superimposable. In
addition, the dose–response curve of EGFR-NCE was the only
one displaying a threshold-controlled behaviour, since both
EGFR-CME and EGFR-total internalization showed comple-
tely different behaviours that did not match that of EGFR
ubiquitination (Figure 9C).
Since the above result establishes a stringent correlation
between EGFR ubiquitination and EGFR-NCE, we exploited
the add-back mutants to investigate whether they are also
Table I Presence of EGFR-NCE in various cell lines






Control 0.30 0.15 Yes
Cl-KD 0.08 0.08
Fil. 0.30 0.08
Cl-KDþ Fil. 0.08 0.03
Dyn-KD 0.07 0.03
Hela Milan EGFR KD (0.7105)
Control 0.24 0.32 Yes
Cl-KD 0.09 0.23
Fil. 0.21 0.24
Cl-KDþ Fil. 0.07 0.04
HeLa Oslo (0.8105)
Control 0.30 0.30 No
Cl-KD 0.08 0.08
Table I (Continued )






Cl-KDþ Fil. 0.08 0.08
NR6-EGFR (2.5105)
Control 0.11 0.11 Yes
Cl-KD 0.03 0.06
Fil. 0.11 0.08
Cl-KDþ Fil. 0.03 0.03
A431 (1.4106)




















Control 0.23 0.13 No
Cl-KD 0.04 0.02
Dyn-KD 0.04 0.02
The presence of an EGFR-NCE pathway in the indicated cell lines
was evaluated by comparing the internalization curves of WT
versus clathrin-KD cells or dynamin-KD (see Supplementary
Figure 9 for estimation of the KD level), or by comparing WT
versus filipin-treated cells, and calculating the endocytic rate
constants (Ke or Ke obs) as explained in detail in Supplementary
Experimental Procedures (section—Definition of EGFR-NCE and
experimental determination of CME and NCE of the EGFR—). Cells
were also subjected to 125I-EGF saturation binding assays to
measure EGFR surface number/cell. Results are the average of
triplicate points (s.e.m.o10%) and representative of at least two
independent experiments. We would like to draw attention to the
comparison between two different HeLa cell isolates, HeLa Milan
and HeLa Oslo. Our previous studies (Sigismund et al, 2008;
Sigismund et al, 2005) have shown that HeLa cells display EGFR-
NCE. Another study, however, showed that the same type of cells
only display EGFR-CME (Kazazic et al, 2006). To resolve the
discrepancy, we compared the HeLa isolates used in both studies
(HeLa Milan (our isolate)) and HeLa Oslo (kindly provided by IH
Madshus, University of Oslo, Norway)) under the same
experimental conditions. We were able to confirm the findings of
both studies, with HeLa Milan, but not HeLa Oslo, displaying
EGFR-NCE. In addition, since we observed that HeLa Milan
displayed Bfour-fold more surface EGFRs than HeLa Oslo
(B3.0105 EGFRs/cell, versus B0.8105 EGFRs/cell,
respectively), we investigated whether the differences in EGFR-NCE
could be ascribed to the different levels of expression of the
receptor. To this end, we attenuated the expression of EGFR in
HeLa Milan by EGFR-KD (HeLa Milan EGFR-KD, 0.7105 EGFRs/
cell) and tested the presence of EGFR-NCE. Also in this case, as
shown in the panel, the cells displayed NCE of the EGFR.
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mechanistically linked. We analysed the EGF dose–response
curves for EGFR internalization (assessing the CME and NCE
component separately) and for EGFR ubiquitination of the
WT receptor versus the add-back mutants. In Figure 9D, we
show a graphical summary of the results (see also
Supplementary Figure 12 for a number of controls pertinent
to these experiments). The 1045þ mutant displayed both
reduction and lack of a clear threshold effect for NCE, with
respect to EGFR-WT. In addition, the profile of the NCE curve
of this mutant was practically superimposable with that of its
ubiquitination (Figure 9D, actual measurements are in
Figure 9E-right for NCE and Figure 8C for Ub, see also
Supplementary Figure 12B for additional comparisons of
internalization and Ub curves in the 1045þ mutant).
Conversely, in the 1045/1068/1086þ mutant, we observed
restoration of the NCE threshold effect and of the magnitude
of internalization through this pathway, with an EGF dose–
response curve superimposable to that of EGFR-WT. Also in
this case, the NCE curves were very similar to the EGFR-Ub
curves (Figure 9D, actual measurements are in Figure
9E-right for NCE and Figure 8C for Ub). Importantly, the
correlation between EGFR ubiquitination and internalization
held true only for NCE and not for CME, since the EGF dose–
response curve of CME did not display any threshold beha-
viour, for EGFR-WT and for the 1045/1068/1086þ mutant
(Figure 9E-centre). Finally, the presence of the double-threshold
effect (for EGFR-NCE and EGFR ubiquitination) in the
1045/1068/1086þ mutant was clearly based on cooperativity
between the 1045 and 1068/1086 phosphosites, since the
1068/1086þ mutant displayed negligible ubiquitination
(Figure 7E) and NCE (Supplementary Figure 12A).
The sum of the above results shows that a naı¨ve EGFR
backbone can be rendered competent for both NCE and
ubiquitination, and for their threshold behaviours, by the
same combination of re-engineered pY sites. Thus, the ubi-
quitination threshold is mechanistically linked to the NCE
internalization threshold of the EGFR.
Discussion
In this study, we demonstrate that ubiquitination of the EGFR
at the PM is threshold controlled. EGFR-NCE is also threshold
controlled, and the EGF dose–response curves of the two
events correlate stringently. Indeed, we show that EGFR-NCE
Figure 9 EGFR ubiquitination and EGFR-NCE are mechanistically linked. (A) 125I-EGF internalization kinetics in control HeLa cells or upon KD
of the indicated proteins at low (1ng/ml, top) or high EGF dose (30ng/ml, bottom). Results are expressed as internalization rate constants (Ke
or Ke obs, see Supplementary Experimental Procedures) and are the mean of triplicate experiments. (B) Dose–response curves of EGFR-NCE
and EGFR ubiquitination (measured by ELISA, forward approach) in HeLa cells. (B) Dose–response curves of 125I-EGF internalization in HeLa
cells. Total internalization, CME and NCE are shown, determined as explained in Supplementary data. (C) EGF dose–response curves of EGFR-
NCE and EGFR ubiquitination (measured by ELISA, forward approach) in NR6 cells stably expressing EGFR-WT or the indicated add-back
mutants. Symbols and error bars are not shown to avoid overcrowding of the figure; actual data are from Figures 8C (for EGFR-Ub) and
Figure 9E (for EGFR-NCE). (D) Dose–response curves of 125I-EGF internalization in NR6 cells expressing EGFR-WT or the indicated add-back
mutants. Total internalization, CME and NCE are shown, determined as explained in Supplementary Experimental Procedures.
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is mechanistically linked to EGFR ubiquitination. Thus, data
strongly argue that ubiquitination acts as a molecular switch,
which allows the cell to convert a linear EGF signal
(a gradient of ligand concentration) into an on–off switch
for the activation of NCE, ultimately regulating EGFR fate.
A mechanism of conversion of a graded signal into
a threshold-controlled response for the EGFR
We have uncovered here a novel mode of EGFR-dependent
signal transduction, which does not follow a simple linear
input-4output relationship. We provided a mechanistic
explanation for how the ubiquitination threshold is generated
as a function of ligand concentration. This is achieved through
a pY-based mechanism, relying on EGFR-pY1045 and EGFR-
pY1068/1086, which controls the recruitment of the
Cbl:Grb2 complex to the EGFR. The phosphorylation of
individual Tyr followed a gradual, hyperbolic increase,
which translates in an almost linear dose–response curve
when a log scale is used (Figures 1B and D and
Supplementary Figure 1B). This is consistent with the possi-
bility that each phosphorylation event is independent of the
others (as shown in Figure 7C and Supplementary Figure 7),
and that therefore the probability of having two given sites
(in our case, Y1045 and either one of Y1068 or Y1086) phos-
phorylated on the same EGFR molecule increases nonlinearly
as a function of ligand concentration, and becomes significant
only when a critical EGF concentration is reached. Indeed, we
obtained direct experimental proof that the concomitant pre-
sence of pY1045 and pY1068 on the same receptor moiety
increases sharply and non-gradually as a function of ligand
(Figure 7A). A scenario can, therefore, be envisioned under
which—at high doses of ligand—the simultaneous presence of
the two binding sites (pY1045 and pY1068/pY1086) allows for
efficient recruitment of the Cbl:Grb2 complex. In addition, a
bidented interaction might also be required to properly posi-
tion Cbl, with respect to the receptor, for efficient catalysis.
We note that while we demonstrated that the simultaneous
phosphorylation of pY1045 and pY1068/pY1086 is necessary
for the threshold effect, this does not mean that it is also
sufficient, as other events might concur to its determination.
In particular, we note that the cooperative binding of the
Cbl/Grb2 complex to EGFR is also, most likely, required. In
this scenario, the Cbl:Grb2 complex would function as an
avidity-driven coincidence detector of the double pY-based
signal generated nonlinearly on an individual EGFR moiety.
In addition, other sources of nonlinearity, such as effects of
phosphatases and de-ubiquitinases (Ostman et al, 2006;
Avraham and Yarden, 2011; Clague et al, 2012), might
contribute to the magnitude and/or to the temporal
dimension of the observed phenotypes in vivo. Finally,
additional Cbl regulatory loops likely have a role in the
control of EGFR ubiquitination. Indeed, Cbl is subjected to
multiple regulations within the cell (Ryan et al, 2006),
including dimerization (which might in principle act both
as positive or negative regulator, (Kozlov et al, 2007;
Peschard et al, 2007)), direct competition with its binding
partners and/or enzymatic activity (e.g., Sprouty, b-PIX, (Wu
et al, 2003; Haglund et al, 2005; Schmidt et al, 2006;
Kim et al, 2007)), and signalling-dependent degradation
(e.g., mediated by Src and HECT-family ligases, (Yokouchi
et al, 2001; Bao et al, 2003; Magnifico et al, 2003)). Thus, our
proposed mechanism of ‘cooperative regulation’ should be
considered as a minimal explanation or, in other words, as
representative of a fundamental layer of regulation on which
other layers can add, either at the PM or—as endocytosis
proceeds—in other subcellular compartments.
One interesting question is whether other receptor systems
are similarly regulated. The Met receptor might be one such
candidate, since Cbl can also be recruited to this receptor
either through direct interaction with phosphotyrosine, or
indirectly through Grb2 (Peschard et al, 2001; Peschard and
Park, 2007). Since Met is ubiquitinated by Cbl (Peschard et al,
2001), it will be interesting to analyse whether Met
ubiquitination is also a threshold-controlled process.
The ubiquitination threshold controls the activation
of the NCE mode of EGFR internalization
We have previously shown that EGFR-NCE is switched on
only at relatively high ligand doses (Sigismund et al, 2005,
2008). In this study, we refine these observations by
demonstrating that EGFR-NCE is also threshold controlled.
The notion of EGFR-NCE has generated a degree of
controversy, as two studies have failed to detect a NCE
pathway for the EGFR (Kazazic et al, 2006; Rappoport and
Simon, 2009). By analysing a panel of cell lines, we found
that the majority of them, but not all, displayed the EGFR-
NCE pathway (Table I). This result has two implications: i) it
shows that, at least in culture, the pathway is context
dependent, thus resolving the discrepancies in the literature, ii)
it shows that EGFR-NCE is a frequent occurrence and not
limited to a single-cell system. One puzzling discrepancy
between our previous studies (Sigismund et al, 2005, 2008)
and another published one (Kazazic et al, 2006) is that HeLa
cells were used in both studies, with rather different results.
We compared the two HeLa isolates in question under the
same experimental conditions and confirmed both sets of
published results. Our HeLa (HeLa Milan) displayed EGFR-
NCE, while the other isolate (HeLa Oslo, (Kazazic et al,
2006)) did not (Table I). Importantly, both HeLa isolates
display threshold-controlled EGFR ubiquitination (our
unpublished results). Other mechanisms, likely downstream
of receptor ubiquitination, are therefore responsible for
the observed differences in NCE in the two HeLa isolates.
We are currently investigating the molecular determinants of
the NCE pathway, to clarify this issue.
Since EGFR ubiquitination and EGFR-NCE are both thresh-
old controlled, an obvious question is whether they are
mechanistically linked. We provide several lines of evidence
in this direction: i) the ubiquitination threshold effect
occurred at the PM, and it is thus compatible with its involve-
ment in the internalization step (Figure 3); ii) both the
ubiquitination and the NCE thresholds occurred within iden-
tical ranges of EGF concentrations (Figures 9B and D); iii) Cbl
was shown to be absolutely required for EGFR-NCE
(Figure 9A); iv) the significant reduction in EGFR ubiquitina-
tion, achieved in EGFR mutants defective in Cbl recruitment
(EGFR-Y1045/68/86F, Supplementary Figure 6F) was associated
to abrogation of EGFR-NCE; v) by exploiting an add-back
strategy, we could precisely reconstruct, on a ubiquitination-
defective/NCE-defective EGFR backbone, the molecular
determinants (pY1045 and pY1068/1086) that cause the
simultaneous acquisition of both ubiquitination and interna-
lization by NCE (Figures 8 and 9D); vi) in this latter series of
experiments, the cooperative behaviour between pY1045 and
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pY1068/1086 was responsible for the re-creation of threshold
behaviour for both EGFR ubiquitination and EGFR-NCE.
The mechanism through which EGFR-Ub is coupled to NCE
remains to be established. An ultrasensitive sorting mechan-
ism has previously been proposed for the recruitment of
EGFR to NCE, in which saturation of the dominant CME
pathway accounted for the sorting of EGFR into the alter-
native NCE pathway at high ligand concentrations (Schmidt-
Glenewinkel et al, 2008). In this ‘sorting’ model, different
endocytic routes ‘consume’ the same form of the receptor.
Our present results, while not excluding that some form of
saturation of the clathrin pathway might concur, are more
readily compatible with a model in which EGFR
ubiquitination is a ‘functional’ signal that diverts activated
tyrosine phosphorylated EGFR from the CME to the NCE
pathway. This is also consistent with our previous findings
that Ub receptors, such as Eps15/Eps15R and Epsin1, are
indispensable for NCE, while being dispensable for CME in
the EGFR system (Sigismund et al, 2005).
Multiple levels of involvement of Cbl in EGFR
internalization
Our present results reinforce the idea that EGFR ubiquitina-
tion is indispensable for NCE; however, the situation is less
clear for CME. We and others favour the notion that EGFR
ubiquitination is dispensable for CME (Jiang and Sorkin,
2003; Sigismund et al, 2005; Huang et al, 2007; Sigismund
et al, 2008); however, the issue remains controversial
(Madshus and Stang, 2009), and it has been proposed that
ubiquitin might have a non-essential and redundant role in
CME (Goh et al, 2011). In this study, we provide evidence that
a triple mutant (Y1045/1068/1086F) that cannot bind to Cbl
or Grb2, and displays severely reduced ubiquitination
(maximum possible is o3% of WT, Supplementary
Figure 6), showed only a modest reduction in CME, while
being completely defective in NCE (Supplementary Figure 6),
further arguing for the dispensability of EGFR ubiquitination
for EGFR-CME.
Interestingly, the data generated with the 1045þ mutant
point to a role of Cbl in CME that is independent of its ability
to ubiquitinate the EGFR, as also previously proposed (Jiang
and Sorkin, 2003; Huang et al, 2007; Sorkin and Goh, 2009).
Indeed, the re-introduction of the single Y1045 phosphosite in
an otherwise pY-null EGFR backbone was capable of partially
restoring both CME and NCE (Figure 9E and Supplementary
Figure 12A). However, it is unlikely that the restoration of Cbl
binding in the Y1045þ mutant caused the partial rescue of
CME through EGFR ubiquitination, since the EGF dose–
response of CME of this mutant was rather different from
that of its ubiquitination, while the dose–response of its NCE
was congruent with it (Supplementary Figure 12B). We note,
instead, that our results are in agreement with the extant
body of knowledge that indicates that Cbl is directly involved
in CME through its role as an adaptor or as an E3 ligase for
proteins other than the EGFR (Dikic and Schmidt, 2007;
Sorkin and Goh, 2009). Indeed, we know of B150 proteins
that bind to, or are regulated by, Cbl (for a review, see
(Schmidt and Dikic, 2005)), many of which are involved in
CME of RTKs. It must be acknowledged that pY1045 might
bind to proteins other than Cbl, although no evidence in this
direction is present in the literature.
The sum of our results, therefore, argues that cells have
evolved distinct mechanisms of internalization, by diversify-
ing the functions of the same (at least in part) molecular
machinery. Cbl exemplifies this concept by possibly function-
ing in CME as an adaptor or E3 ligase for proteins other than
EGFR, and in NCE as an EGFR-E3 ligase responsible for
threshold-activated ubiquitination of the receptor.
Biological implications
In our previous work, we have shown that NCE-internalized
EGFRs are destined to degradation, while the majority of
CME endocytic events lead to recycling to the PM (Sigismund
et al, 2008). We proposed that this mechanism might have
evolved to protect the cell from overstimulation, since a
sizable EGFR fraction would be directed to NCE-mediated
degradation, in the presence of high EGF (Sigismund et al,
2008). The identification of threshold control in the activation
of EGFR-NCE allows us now to propose a homoeostatic
mechanism, which controls the number of EGFRs on the
PM, that can help us to understand how the interplay
between endocytic routes determines biological outcome.
Several reactions are needed to induce the phosphorylation
of EGFR: ligand binding, conformational changes of the
EGFR, EGFR dimerization, kinase activation. The dimeriza-
tion step is obviously highly dependent on the levels of EGFR
at the PM. We propose that when EGF exceeds a critical
concentration threshold ubiquitination is triggered, which
leads to a sharp activation of the major degradative route,
NCE. This causes a decrease in the surface levels of EGFR.
Under these conditions, fewer EGFR dimers can form; EGFR
phosphorylation would decrease and all the threshold effects
herein described (phosphorylation, Cbl recruitment, ubiqui-
tination) would cease, determining a sharp decrease of NCE.
This would direct an increasing proportion of EGFRs to CME,
thereby salvaging them from degradation, through recycling,
a process that in the long term would ensure the recovery of
EGFR at the PM. The final balance would be the preservation
of enough receptor on the PM (and in signalling-competent
endocytic compartments) to guarantee the persistence of
signalling necessary for biological output. Under this scenar-
io, the Cbl-centred threshold signal conversion herein
described permits proper signal maintenance, with tolerance
for a wide range of ligand concentrations. We are presently
testing ad hoc mathematical models to verify this hypothesis.
Materials and methods
Reagents and antibodies
EGF was from PeproTech; rhodamine-EGF from Molecular Probes;
125I-EGF and 125I-Tf were from PerkinElmer; AG1478 was from
Calbiochem. Antibodies were: a polyclonal anti-EGFR (made in
house, directed against aa 1172–1186 of human EGFR), two mono-
clonal anti-EGFR antibodies directed against the extracellular do-
main of human EGFR (m108 hybridoma, American Type Culture
Collection (ATCC), (Aboud-Pirak et al, 1988) and Ab-1,
Calbiochem), anti-EGFR phospho-specific antibodies (Cell
Signaling), anti-pY (4G10, Upstate), anti-Ub P4D1 (Santa Cruz,
used in all anti-Ub IBs, unless otherwise specified), anti-Ub FK2
(BIOMOL, used in all ELISAs, see Supplementary Experimental
Procedures, and in some control experiments, as indicated in the
figures), anti-Ub ZTA10 (made in house, monoclonal; used in some
control experiments, as indicated in the figures), anti-tubulin (Santa
Cruz), anti-vinculin (Sigma), anti-dynamin (Santa Cruz), anti-Grb2
(Santa Cruz and BD), anti-c-Cbl (Santa Cruz and BD), anti-Cbl-b
(BD), anti-Shc (BD), anti-GST (in-house polyclonal).
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Cell lines and constructs
HeLa, NR6 and CHO cells were cultured as previously described
(Haglund et al, 2003; Sigismund et al, 2005). NR6 are fibroblasts
devoid of endogenous EGFR (Pruss and Herschman, 1977). HeLa
Oslo cells were kindly provided by IH Madshus (University of Oslo,
Norway). All other cell lines were obtained from ATCC. The EGFR
mutants were generated by site-directed mutagenesis of the human
EGFR cDNA and expressed in the pBABE-puro retroviral vector;
their stable expression in NR6 was obtained by infection followed
by puromycin selection. GST-Cbl was engineered starting from a Cbl
cDNA kindly provided by Y Yarden (Weizmann Institute, Israel). All
clones were sequence-verified; details are available upon request.
RNA interference experiments
Silencing of the clathrin heavy chain, dynamin 2, c-Cbl/Cbl-b or
Grb2 in HeLa cells was by transient transfection of siRNA oligos
(from Dharmacon or Invitrogen) using Lipofectamine RNAiMAX
(Invitrogen), following the manufacturer’s instructions. Cells were
subjected to double transfection, ‘reverse’ (cells in suspension) on
day 1 and ‘forward’ (adherent cells) on day 2. Cells were then
processed and analysed 48–72 h after second transfection.
Two different RNAi oligos were used to target the clathrin heavy
chain in HeLa cells:
Oligo 1: 50-CCTGCGGTCTGGAGTCAAC-30, from Dharmacon
(Hinrichsen et al, 2003);
Oligo 2: 50-GAAGAACTCTTTGCCCGGAAATTTA-30, from Invitrogen
(Sigismund et al, 2008).
In all of the reported assays, the two targeting oligos yielded
comparable results. Results obtained with Oligo 1 are shown. For
each oligo, a mismatched control was designed by introducing at
least four mutations in the sequence, and was used in all experi-
ments. The sequences of the mismatched control oligos are:
Oligo 1 control: 50-TCGAATACGAACACCTAT-30
Oligo 2 control: 50-GAATCATTCCGTGCCAAGTAGATTA-30
To silence the clathrin heavy chain in NR6 cells, Oligo 2 was used,
since the human and mouse sequences are identical in that region
(purchased form Invitrogen).
Two different RNAi oligos were used to target dynamin 2
(Dharmacon, (Huang et al, 2004)):
Oligo 2: 50-GACATGATCCTGCAGTTCA-30;
Oligo 3: 50-GAGCGAATCGTCACCACTT-30.
In all assays, the two targeting oligos yielded comparable results.
Results obtained with Oligo 3 only are shown in Figure 3 of the
main text. A mismatched sequence of Oligo 3 was used as control.
Oligo 3 control: 50-GACGGATACGTACCCCATT-30.
To silence c-Cbl and Cbl-b, two different oligos for each family





The two targeting oligos yielded comparable results. Results
obtained with UTR1 (for both c-Cbl and Cbl-b) are shown in
Figures 4B and C of the main text. In this set of experiments,
non-targeting oligo control was purchased from Qiagen (#1027281).




c-Cbl, Cbl-b and Cbl-c mRNA levels were determined through
the TaqMAN assays Hs00231981_m1, Hs00180288_m1 and
Hs00201650_m1, respectively.
Biochemical assays
Cell lysis was performed in denaturing conditions in RIPA buffer
(50mM Tris–HCl, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 1%
Sodium deoxycholate, 0.1% SDS). For co-IP experiments, lysis was
in non-denaturing conditions in JS buffer (50mM HEPES pH 7.5,
50mM NaCl, 1% glycerol, 1% Triton X-100, 1.5mM MgCl, 25mM
EGTA). To exclude the presence of co-immunoprecipitating
proteins, for the ELISAs and for the IP in Figure 7A, lysis was
performed in RIPA buffer containing 1% SDS, followed by clarifica-
tion for 1 h at 120 000 g and dilution to a final SDS concentration of
0.2%. This same lysis condition was also used to repeat some of the
critical IP experiments to analyse EGFR-Ub and pY curves, with
results indistinguishable from those obtained by lysing cells in RIPA
buffer (Supplementary Figure 1D). All buffers were supplemented
with a protease inhibitor cocktail (Calbiochem) and phosphatase
inhibitors (20mM Na-pyrophosphate pH 7.5, 50mM NaF, 10mM
Na3VO4 pH 7.5). IP and co-IP assay were performed using 500 mg
or 1mg of lysate, respectively. IB was performed as described
previously (Polo et al, 2002; Penengo et al, 2006).
Co-IP assays between Cbl and EGFR mutants in NR6 cells
(Figure 8A) were performed starting from 1mg (for EGFR WT and
Y1045/68/86þ ) or 2mg of lysate (for the 1045þ mutant), for each
condition. Washes were then performed in JS buffer (for EGFR WT
and the 1045/68/86þ mutant) or in JS buffer containing a five-fold
reduced amount of Triton X-100 (0.2%) for the 1045þ mutant.
For the GST pull-down assays of Figure 6D, 10mg of GST-Cbl were
incubated in the presence or absence of a ten-fold molar excess of
bacterially produced purified Grb2 for 30min at 41C in JS buffer,
and then challenged with 500 mg of lysate from EGF-stimulated
HeLa cells. Beads were washed thrice with JS buffer plus 0.05% SDS
plus proteases and phosphatases inhibitors.
Signal quantification and normalization
Quantification of IBs was performed using the Photoshop Extended
Measurement function of Photoshop and measuring the mean grey
value. In all experiments, densitometry was performed on different
exposures of the blots and results were obtained in the linear phase
of the exposure. Signals were corrected for the amounts of loaded
proteins (typically by correcting for the amount of immunoprecipi-
tated proteins, determined in parallel gels, always shown in the
various Figures).
In general, results were expressed as ‘% of max’, which means
that they were normalized to the maximal numerical value obtained
in the curve (typically at 100 ng/ml of EGF). When multiple curves
are shown in the same graph and are expressed as ‘% of max’,
therefore, each curve is normalized to its own maximal level. In
some case, however, it was more appropriate to express values such
as to allow a direct quantitative comparison, as for instance when
the effects of different mutant EGFRs were compared. In these
cases, results are expressed as ‘arbitrary units’ (a.u.) on a scale
0–100 in which 100 represents the maximal numeric value obtained
with EGFR-WT (typically at 100 ng/ml of EGF).
Results obtained in ELISAs are similarly expressed either as ‘% of
max’ or as ‘a.u.’ (100¼max EGFR-WT).
Results of all IB or ELISAs are average (±s.d.) of at least three
independent experiments.
ELISAs for EGFR ubiquitination and phosphorylation
For the ELISA-based, we used the DELFIA (Dissociation Enhanced
Lanthanide Fluoroimmunoassay) technology from PerkinElmer. It is
based on sandwich recognition of a target protein by a capture
antibody and a detection antibody. The capture antibody is immo-
bilized on a solid surface (microwells) directly through non-
covalent bonds. After the addition of the analyte (appropriate cellular
lysate), the detection of signals relies on a lanthanide (Europium)-
conjugated antibody that is able to produce a fluorescent signal
upon enhancement with acidic enhancement buffer. Lanthanide
ions are released in solution at low pH and they rapidly form new,
highly stable fluorescent chelates. The fluorescence of the lantha-
nide chelate is amplified 1–10 million times by this enhancement
step and it develops a signal in 5min that is stable for up to 8 h
(additional details of the experimental protocol are in the legend to
Supplementary Figures 2A and B). Plate preparation, analyte
incubation and antibody detection were according to the manufac-
turer’s instruction. Briefly, microwells plates were coated with the
capturing antibody (see below). Blocking was performed for 2 h
with BSA 2% in PBS. 25–50mg of lysates from HeLa or NR6 cells,
stimulated with the indicated concentration of EGF, were incubated
overnight at 41C. Lysates were prepared in RIPA/1% SDS buffer and
diluted to 0.2% SDS before incubation step. After three washes,
wells were incubated with primary antibodies, diluted at 1mg/ml in
assay buffer, for 1 h at RT. After three washes, anti-mouse or rabbit
Europium-labeled secondary antibodies (1mg/ml in assay buffer)
were added for an additional hour. After three washes and treat-
ment with enhancement solution, fluorescence was measured with
EnVision instrument (excitation at 340nm and emission at 615 nm).
Capturing and detecting antibodies differed depending on
whether a forward or reverse approach was performed (see
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Supplementary Figures 2A and B for a scheme of the two
procedures):








against Ub (FK2), pY
(4G10), pY1068, or EGFR












against aa 1172–1186 of
human EGFR (1mg/ml)
Sample preparation for MS analysis
Immunopurified EGFR samples were acetone precipitated. Protein
pellets were suspended in 30ml Laemmli buffer. Proteins were resolved
by SDS–PAGE on a gradient gel (4–12% Tris–HCl Precast Gel,
Invitrogen) and stained with Colloidal Coomassie. Enzymatic
in-gel digestion was performed essentially as previously described
(Shevchenko et al, 2006). Briefly, samples were subjected to
reduction in 10mM DTT for 1h at 561C, followed by alkylation with
55mM iodoacetamide for 45min at RT, in the dark. Digestion was
carried out saturating the gel with 12.5ng/ml sequencing grade-
modified trypsin (Promega) in 50mM ammonium bicarbonate, o/n.
Peptide mixtures were acidified with tri-fluoro acetic acid (TFA, final
concentration 3%), extracted from gel slices with two rounds of washes
(in 30% acetonitrile (ACN)/ 3% TFA and then in 100% ACN,
respectively) and concentrated to 100ml in a vacuum concentrator
(Eppendorf). About 70% of each sample was loaded onto home-
made C18-Stage Tips, for concentration and desalting prior LC-MS/
MS analysis (Rappsilber et al, 2007). The remaining 30%was subjected
to titanium sphere-chromatography (TiO2), for phosphopeptide
enrichment and analysis (Supplementary Experimental Procedures).
For comparative MS analysis, we employed SILAC (stable isotope
labelling with amino acids in cell culture), as detailed in
Supplementary data.
EGFR in vitro ubiquitination assay
A baculovirus-produced GST-EGFR cytoplasmic tail (aa 696–end,
Millipore, 250ng) was subjected to in vitro autophosphorylation for
1.5 h at 301C in kinase buffer (2mM ATP, 10mM MnCl2, 0.8M
(NH4)2SO4). Phosphorylated GST-EGFR tail was then bound to
Glutathione Sepharose 4B (GE Healthcare), washed thrice in YY
buffer (50mM HEPES, pH 7.5, 10% glycerol, 150mM NaCl, 1%
Triton, 1mM EDTA, 1mM EGTA plus protease/phosphatase inhibi-
tors) and subjected to an in vitro ubiquitination reaction for 1 h at
301C in Ub buffer (250mM Tris-HCl pH 7.6, 50mM MgCl2, 1M
NaCl, 1mM DTT, 2mM ATP, plus ATP regeneration system, Sigma),
with the following amount of purified enzymes: 100 ng of E1
(purified from baculovirus), 500 ng of E2 (His-tagged UbcH5c/
Ube2D3, purified from bacteria), 500ng of Cbl as E3 (purified
from bacteria), 1 mg of Ub (Sigma), with or without Grb2 (purified
from bacteria). Beads were then washed four times in YY buffer and
eluted in Laemmli buffer. Enzymes were purified as described
(Maspero et al, 2011).
Internalization assays
Internalization of 125I-EGF was performed as described (Haglund
et al, 2003; Tosoni et al, 2005). In filipin experiments, cells were pre-
incubated for 30min with 0.5–1mg/ml of filipin (Sigma), before
performing internalization assays in the presence of high
concentrations of 125I-EGF; internalization at low concentrations
of 125I-EGF and 125I-Tf was also measured in the presence of filipin
(data not shown), to exclude non-specific effects (see also
Sigismund et al, 2008). Note that, both at high and low EGF
concentrations, B20–25% of the internalization events were
insensitive to the combined clathrin-KD and filipin treatment,
both in HeLa and NR6 cells (see for instance, Table I and
Supplementary Figures 8A and B). We refer to this component
operationally as ‘background endocytosis’ (BE). In Figures 9B–E
and in Supplementary Figure 12B, this background (that was
experimentally measured in each experiment) was subtracted, to
obtain parameters unequivocally ascribable to CME and NCE.
Additional details and analyses of the various EGF internalization
pathways are in Supplementary data (section—Definition of EGFR-
NCE and experimental determination of CME and NCE of the EGFR –)
and in the legend to Supplementary Figure 8.
Measurement of surface EGFRs
Surface EGFRs (Table I, Figure 7B and Supplementary Figure 6B)
were measured by 125I-EGF saturation binding assay. Serum-starved
HeLa or NR6 cells were incubated on ice for 6 h in the presence of
EGF (100 ng/ml, spiked with 125I-EGF, typically in a 1:20 hot/cold
ratio) in serum-medium supplemented with 0.1% BSA and 20mM
HEPES pH 7.4. Cells were then washed three times with ice-cold
PBS and solubilized in 1M NaOH. After correction for the hot/cold
dilution, the number of EGFRs/cell was deduced from the total
recovered counts, corrected for the specific activity of the radioli-
gand and divided for the number of cells in the plate. Non-specific
binding was measured in the presence of a 200-fold excess of cold
ligands and subtracted from the total counts. Non-specific binding
was never 43–10% of the total counts.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 4.0c
for Mac. Two-way ANOVA with Bonferroni post-tests was used to
analyse the variance in the different treatment conditions (i.e., EGF
concentration) and experimental conditions (i.e., Ub and/or pY
modification; EGFR mutants), and the relative statistical signifi-
cance of their differences. Pearson correlation metric was used to
measure similarity among different experimental conditions.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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